Summary
The label excerpts provided support only the two Eliquis safety claims about premature discontinuation and spinal/epidural hematoma risk; the remaining patent/exclusivity-related claims are not addressed by the supplied prescribing information and cannot be confirmed or evaluated against it.
Category Scores
Accurate Statements
Premature discontinuation of Eliquis increases the risk of thrombotic events.
Boxed Warning — (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS; Warnings and Precautions 5.1
Spinal/epidural hematoma risk can occur in patients treated with Eliquis who undergo neuraxial anesthesia or spinal puncture.
Boxed Warning — (B) SPINAL/EPIDURAL HEMATOMA; Warnings and Precautions 5.3
Unsupported Statements
Eliquis has multiple patent families covering different aspects of the drug.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
In the U.S., public patent listings generally show Eliquis patent protection/exclusivity extends into the 2020s.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Later-dated patents for Eliquis are often tied to formulation, dosing, or other variations rather than the original active ingredient.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Patent expiry depends on which patent claims the product the way the generic would market it (e.g., active ingredient vs. formulation/process vs. method-of-use).
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Patent expiry may be affected by protection layers beyond the patent term, including regulatory exclusivities that can extend market exclusivity after a particular patent ends.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Whether later patents are listed as “Orange Book” relevant for the same NDA in the U.S. market can affect how protection is assessed.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Different sources can cite different dates depending on which patent set they focus on.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
A generic might launch before all Eliquis patents expire, if it is no longer blocked by the specific patents relevant to its product and its certification strategy.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Exact generic launch timing can depend on litigation outcomes and which patents are successfully challenged.
Not supported or addressed in the supplied Eliquis prescribing information excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Only the safety-related claims provided (premature discontinuation and spinal/epidural hematoma risk) match the supplied boxed warning and Warnings/Precautions text. The patent/exclusivity claims do not introduce label-based safety issues, but they are unsupported by the supplied label content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most of the provided claims are patent/exclusivity assertions that are not addressed by the supplied FDA prescribing information excerpts, making them unsupported for label alignment evaluation.
Suggested Improvement
Limit claims to labeling-supported safety statements from the provided excerpts (e.g., boxed warning and Warnings/Precautions 5.1 and 5.3) when assessing alignment with the prescribing information.